Chaoran Li1, Tian Li1, Runwei Tang1, Shuai Yuan1, Weihong Zhang1. 1. Department of Breast Surgery, Baoshan Branch, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201900, China.
Abstract
BACKGROUND: Evidence remains inconsistent regarding the potential influence of β-blocker (BB) use on clinical outcomes in women with breast cancer. We aimed to evaluate the association between BB and prognosis of breast cancer in an updated meta-analysis. METHODS: Follow-up studies comparing the clinical outcomes of breast cancer in women with and without use of BB were included by search of PubMed, Embase, and Cochrane's Library. A random-effect model was used to pool the results. RESULTS: Seventeen observational studies were included. Pooled results did not support a significant association between BB use and breast cancer recurrence (risk ratio [RR] = 0.85, 95% confidence interval [CI]: 0.68-1.07, P=0.17), breast cancer related deaths (RR = 0.83, 95% CI: 0.65-1.06, P=0.14), or all-cause deaths (RR = 1.01, 95% CI: 0.91-1.11, P=0.91) in women with breast cancer. Study characteristics such as sample size, definition of BB use, follow-up durations, adjustment of menopausal status, or quality score did not significantly affect the results. Subgroup analyses showed that BB may be associated with a trend of reduced risk of all-cause deaths in women with breast cancer in prospective studies (two datasets, RR = 0.81, P=0.05), but not in retrospective studies (eight datasets, RR = 1.06, P=0.16; P for subgroup analyses = 0.02). CONCLUSIONS: Current evidence from observational studies does not support a significant association between BB use and improved prognosis in women with breast cancer.
BACKGROUND: Evidence remains inconsistent regarding the potential influence of β-blocker (BB) use on clinical outcomes in women with breast cancer. We aimed to evaluate the association between BB and prognosis of breast cancer in an updated meta-analysis. METHODS: Follow-up studies comparing the clinical outcomes of breast cancer in women with and without use of BB were included by search of PubMed, Embase, and Cochrane's Library. A random-effect model was used to pool the results. RESULTS: Seventeen observational studies were included. Pooled results did not support a significant association between BB use and breast cancer recurrence (risk ratio [RR] = 0.85, 95% confidence interval [CI]: 0.68-1.07, P=0.17), breast cancer related deaths (RR = 0.83, 95% CI: 0.65-1.06, P=0.14), or all-cause deaths (RR = 1.01, 95% CI: 0.91-1.11, P=0.91) in women with breast cancer. Study characteristics such as sample size, definition of BB use, follow-up durations, adjustment of menopausal status, or quality score did not significantly affect the results. Subgroup analyses showed that BB may be associated with a trend of reduced risk of all-cause deaths in women with breast cancer in prospective studies (two datasets, RR = 0.81, P=0.05), but not in retrospective studies (eight datasets, RR = 1.06, P=0.16; P for subgroup analyses = 0.02). CONCLUSIONS: Current evidence from observational studies does not support a significant association between BB use and improved prognosis in women with breast cancer.
Authors: Anne Kreklau; Ivonne Nel; Sabine Kasimir-Bauer; Rainer Kimmig; Anna Christina Frackenpohl; Bahriye Aktas Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: José A Carlos-Escalante; Marcela de Jesús-Sánchez; Alejandro Rivas-Castro; Pavel S Pichardo-Rojas; Claudia Arce; Talia Wegman-Ostrosky Journal: Front Oncol Date: 2021-05-20 Impact factor: 6.244